New Brunswick, NJ, June 1, 2012 ― The HealthCare Institute of New Jersey (HINJ) applauds the overwhelming, bipartisan approval by the United States Senate and House of Representatives of legislation that included the reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Medical Device User Fee Act (MDUFA).
The Senate, by a 96 to 1 vote, approved the Food and Drug Administration Safety and Innovation Act (FDASIA) (S. 3187) on May 24. The House, by a 387 to 5 vote, approved the Food and Drug Administration Reform Act of 2012 (HR 5651) on May 30.
The Senate and House versions will be referred to a conference committee for reconciliation of the two bills.
“The Senate and House votes clearly demonstrate bipartisan recognition of PDUFA and MDUFA as vitally important and effective programs that contribute significantly to helping bring innovative, safe medicines and medical technologies and therapies to patients,” said Dean J. Paranicas, HINJ’s president and chief executive officer.
“New Jersey’s Congressional Delegation deserves considerable recognition for their strong and vocal support of this legislation, which will benefit patients across the country and sustain the innovation environment that produces new treatments and cures and drives New Jersey’s workforce and economy,” Paranicas added.
Founded in 1997, the HealthCare Institute of New Jersey (HINJ) serves as the voice for the state’s life sciences industry. It seeks to expand public access to the latest and most innovative treatments for diseases and build awareness of the industry’s impact on New Jersey’s quality of life and economic well-being. It helps to advance the development and implementation of sound public health and business policies that support the interests of New Jersey, its people and its life sciences industry. For information, please visit www.hinj.org.
For additional information, please contact HINJ at (732) 729-9619.